Group 1 - Hangxiao Steel Structure announced that it does not have a "commercial aerospace" business, with its main operations focused on steel structure contracting and related services, and a recent project contributing less than 1% to its 2024 audited revenue [1] - Tianlong Group stated that it has not generated additional revenue from AI tools, which are currently used internally for advertising content creation, and that the overall business operations remain unaffected [1] - Wanxing Technology confirmed that there are no undisclosed significant matters affecting its operations, and its business environment remains stable [2] Group 2 - Yaxing Chemical announced the termination of a share issuance and cash purchase of assets due to market changes and disagreements on asset valuation [2] - Zhejiang Shuculture clarified that its subsidiaries do not engage in GEO business, which has been misreported by media [2] - Luxshare Precision terminated the acquisition of assets from Wintime Technology due to delivery restrictions, with a request for the return of 1.53 billion RMB [3] Group 3 - Jinyu Group reported that its subsidiaries' revenues from specific projects are minimal compared to its overall revenue, with a small contribution from recent contracts [4] - Tongyu Communication highlighted that its stock price has significantly outpaced its fundamentals, indicating potential risks of a price correction [4] - Dongfang Mingzhu noted that the listing process for its investment in Chaoguhuan has uncertainties but currently does not impact its performance [5] Group 4 - Luyin Investment warned of risks associated with its stock price surge, which has increased by 86.92% over the last ten trading days [5] - Puyuan Information stated that its AI software platform is in the early commercialization stage, with limited revenue impact expected [6] - Zhejiang Wenhu Intermediary reported that its GEO business has not yet generated revenue, reflecting uncertainties in market acceptance [6] Group 5 - Xinhua News confirmed that its GEO business lacks a mature profit model and has not generated income [7] - People's Daily stated that it does not engage in GEO business and has not been affected by market rumors [7] - China First Heavy Industries reported minimal involvement in controllable nuclear fusion projects, with no significant revenue generated [8] Group 6 - Xibu Mining announced an increase in copper resources at the Yulong Copper Mine, adding 131.42 million tons of copper metal resources [8] - Jiurui New Materials commenced trial production of a new photoinitiator project, expected to cater to mainstream markets [9] - Tongda Sea indicated that AI-related revenue is low and does not significantly impact overall business performance [10] Group 7 - Zhenai Meijia's stock price has deviated significantly from market indices, prompting caution for investors [11] - Guizhou Moutai approved a new marketing strategy to enhance its sales channels and adapt to consumer demands [12] - Shunhao Co. plans to increase its stake in a subsidiary, reflecting confidence in future business prospects [14] Group 8 - A number of companies, including TCL Technology and Dazhu CNC, forecast significant profit increases for 2025, driven by operational improvements and market demand [19][22] - Long Cable Technology expects a profit increase due to changes in its employee stock plan and market conditions [22] - Jiangsu Electric Power reported a profit increase attributed to higher sales and reduced financial costs [29]

Core Viewpoint - Prolo Pharmaceutical (000739.SZ) announced that its controlling shareholder, Hengdian Group, through its action-in-concert party, Dongyang Hengdian Yushan Sports Leisure Co., Ltd. (referred to as "Yushan Sports"), has increased its shareholding in the company, indicating a positive outlook on the company's future performance [1] Group 1 - Yushan Sports acquired 1,653,500 shares of Prolo Pharmaceutical on January 13, 2026, representing 0.14% of the company's total share capital, with a total investment of approximately RMB 28,695,970 [1] - Following this transaction, the combined shareholding of the controlling shareholder and its action-in-concert parties reached 52.03%, triggering a change in equity that touches the 1% integer multiple [1] Group 2 - Yushan Sports plans to further increase its shareholding within six months starting from January 13, 2026, with a minimum investment of RMB 60 million and a maximum of RMB 120 million, including the amount already invested [1]

证券代码：000739 证券简称：普洛药业 公告编号：2026-04 普洛药业股份有限公司 关于控股股东一致行动人增持公司股份暨权益变动触及 1% 整数倍及后续增持计划的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.普洛药业股份有限公司（以下简称"公司"）于 2026 年 1 月 13 日收到控 股股东横店集团控股有限公司之一致行动人东阳市横店禹山运动休闲有限公司 （以下简称"禹山运动"）出具的《东阳市禹山运动休闲有限公司关于增持普洛 药业股份暨权益变动触及 1%整数倍及后续增持计划的告知函》，2026 年 1 月 13 日，禹山运动通过深圳证券交易所交易系统以集中竞价交易方式增持公司股份 1,653,500 股，占公司总股本的 0.14%，增持金额共计人民币 28,695,970 元，公 司控股股东及其一致行动人合计持有公司股份比例达到 52.03%，权益变动触及 1%整数倍。 2.禹山运动计划自 2026 年 1 月 13 日起 6 个月内，以自有资金或自筹资金通 过集中竞价交易方式增持公司股份，拟增持公司股份金额不低于人民币 0. ...

Group 1 - The core point of the announcement is that Yushan Sports, a concerted action party of the controlling shareholder, has increased its stake in Prologis Pharmaceuticals by acquiring 1.6535 million shares, which represents 0.14% of the total share capital, for a total amount of 28.69597 million yuan [1] - Following this acquisition, the combined shareholding of the controlling shareholder and its concerted action parties has reached 52.03%, triggering a change in equity that touches upon the 1% integer multiple [1] - Yushan Sports plans to further increase its stake in the company within six months starting from January 13, with an investment amount not less than 60 million yuan and not exceeding 120 million yuan (including this acquisition) [1] Group 2 - Yushan Sports has committed to not reducing its holdings during the increase period and the statutory period [1] - The planned increase may be subject to market changes, which could result in partial or complete non-implementation of the plan [1]

Market Overview - The Shanghai Composite Index is at 4164.11 points, slightly above the five-day moving average, with a change of -0.03% [1] - The total trading volume of A-shares is 18505.22 billion yuan, with 228 A-shares breaking through the five-day moving average [1] Stocks with Significant Deviation - The stocks with the largest deviation from the five-day moving average include: - Dapeng Industrial (证券代: 920091) with a deviation of 8.06% and a price increase of 10.14% [1] - Hongxing Development (证券代: 600367) with a deviation of 7.42% and a price increase of 10.01% [1] - Prologis Pharmaceutical (证券代: 000739) with a deviation of 7.37% and a price increase of 10.03% [1] Additional Notable Stocks - Other notable stocks with significant price movements include: - Lek Electric (证券代: 603355) with a deviation of 7.20% and a price increase of 9.99% [1] - Tianyi Medical (证券代: 301097) with a deviation of 6.87% and a price increase of 11.59% [1] - Meihu Co., Ltd. (证券代: 603319) with a deviation of 6.30% and a price increase of 7.73% [1] Stocks with Smaller Deviations - Stocks that have just crossed the five-day moving average with smaller deviations include: - Cangge Mining (证券代: 300300) with a deviation of 3.83% and a price increase of 5.01% [1] - ST Xiangxue (证券代: 300147) with a deviation of 3.57% and a price increase of 4.79% [1] - Shandong Molong (证券代: 002490) with a deviation of 3.43% and a price increase of 5.62% [1]

Core Viewpoint - The company emphasizes that its stock price is influenced by various factors including macroeconomic environment, policy landscape, industry cycles, and operational performance, leading to a relatively stable stock price recently [1] Group 1: Strategic Initiatives - The company is accelerating its strategic transformation and upgrading efforts while continuously strengthening its core competitiveness [1] - The CDMO (Contract Development and Manufacturing Organization) business is experiencing sustained growth and has become the highest gross margin segment for the company, serving as a major driver for performance improvement [1] Group 2: Shareholder Returns - The company places significant importance on shareholder returns, consistently implementing cash dividends and share buybacks to enhance shareholder value [1] - The company aims to genuinely allow investors to share in the growth and success of the company [1]

Group 1 - The company acknowledges that its stock price is influenced by various factors including macroeconomic environment, policy landscape, industry cycles, and operational performance [1] - The company emphasizes its commitment to value creation and sharing, highlighting its strategic transformation and enhancement of core competitiveness [1] - The CDMO business segment is noted as the highest gross margin area and a key driver of the company's performance growth [1] Group 2 - The company is focused on enhancing shareholder returns through cash dividends and share buybacks [1] - The management expresses gratitude for investor attention and aims to ensure that investors share in the company's development achievements [1]

2025年11月28日，公司通过回购专用证券账户以集中竞价方式实施了首次回 购，首次回购公司股份230,000股，占公司目前总股本的0.02%，最高成交价为 16.00元/股，最低成交价为15.91元/股，成交总金额为3,669,192元（不含交易 费用）。具体内容详见公司于2025年12月1日披露的《关于实施2025年第二次回 购公司股份方案之首次回购股份暨进展公告》（公告编号：2025-74）。 根据《深圳证券交易所上市公司自律监管指引第9号——回购股份》等相关 规定，公司实施股份回购期间应当在每个月的前三个交易日内披露截至上月末的 回购进展情况；回购股份占公司总股本的比例每增加1%的，将在事实发生之日起 三个交易日内予以披露。具体内容详见公司于2025年12月25日披露的《关于回购 股份比例达到1%的进展公告》（公告编号：2025-78），于2026年1月6日披露的 《关于回购公司股份的进展公告》（公告编号：2026-01）。 证券代码：000739 证券简称：普洛药业 公告编号：2026-03 普洛药业股份有限公司 关于 2025 年第二次股份回购完成暨股份变动的公告 本公司及董事会全体成员保证信息披 ...

格隆汇1月9日丨普洛药业(000739.SZ)公布，截至2026年1月8日，本次回购方案已实施完毕。公司实际 回购时间区间为2025年11月28日至2026年1月8日，公司通过股票回购专用证券账户以集中竞价交易方式 累计回购公司股份22,090,000股，占公司目前总股本的1.91%，最高成交价16.85元/股，最低成交价15.71 元/股，成交总金额为人民币359,947,227.50元（不含交易费用）,回购资金总额为人民币359,987,287.27 元（含交易费用）。 ...

（记者 曾健辉） 每经头条（nbdtoutiao）——独家对话特斯拉FSD跨美第一人：4400公里"零接管"，手没碰过方向盘！作 为激光雷达销售员，他为何站队马斯克的"纯视觉"？ 每经AI快讯，普洛药业1月9日晚间发布公告称，截至2026年1月8日，本次回购方案已实施完毕。公司 实际回购时间区间为2025年11月28日至2026年1月8日，公司通过股票回购专用证券账户以集中竞价交易 方式累计回购公司股份2209万股，占公司目前总股本的1.91%，最高成交价16.85元/股，最低成交价 15.71元/股，成交总金额为人民币约3.6亿元回购资金总额为人民币约3.6亿元。 ...